Research Radartracking 1,762 published studies · 471 human · 11 safety signals · 58 clinical trials · 44 cancer pages · updated Sep 2026Open the Research Map →

Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language. A person reviews each one; registered human trials and meta-analyses that pass every automated check post without waiting for that review.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract. A person reviews them; the strongest tier — registered human trials and meta-analyses that pass every automated check — is posted first and reviewed after. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.
Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:
Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism
Showing studies that mention “ovarian epithelial carcinoma”.
1 of 200 studies
Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 381

FOXA1 expression and its association with mucin expression and KRAS mutation in ovarian mucinous tumors: implications for tumor progression and differentiation

Virchows Archiv : an international journal of pathology · Sep 2025

ovarian mucinous tumorsovarian epithelial carcinomas

The authors examined FOXA1 protein expression by immunohistochemistry and KRAS mutation status across normal/benign ovarian tissues, mucinous ovarian tumors, and other ovarian epithelial carcinomas (total n=381). FOXA1 was commonly expressed in mucinous tumors and its expression correlated with MUC2; KRAS mutations increased with malignancy but were relatively enriched in FOXA1-negative cystadenomas. The authors propose that co-occurrence of KRAS mutation and FOXA1 expression may relate to tumor progression and intestinal-type differentiation.

Reported effects: FOXA1 expression in cystadenomas 73.6% · FOXA1 expression in borderline tumors 91.4% · +7 more

Key findings
  • FOXA1 expression was significantly associated with mucinous histology in ovarian epithelial carcinomas (P < 0.001).
  • In mucinous tumors, FOXA1 was expressed in 73.6% of cystadenomas, 91.4% of borderline tumors, 100% of borderline tumors with intraepithelial carcinomas, and 87.5% of carcinomas.
  • MUC2 expression progressively increased from mucinous cystadenomas to borderline tumors (P < 0.050) and significantly correlated with FOXA1 expression (P = 0.024).
  • The prevalence of KRAS mutations tended to increase with the malignancy of mucinous tumors (P < 0.050).
  • KRAS mutations were significantly enriched in FOXA1-negative cystadenomas compared with FOXA1-positive cystadenomas (P < 0.050).
  • A stepwise increase was noted in the percentage of both KRAS mutations and FOXA1 expression from cystadenoma to carcinoma.
Limitations: Observational analysis of tumor specimens only (no functional or mechanistic experiments reported).; No clinical outcome or survival data were reported to link findings to prognosis.; Causality between FOXA1 expression, KRAS mutation, and tumor progression or differentiation cannot be established from the methods described..

AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed